"In twelve months this should see a share price at approximately $50. A takeover at that time, with risks reduced and future potential identifiable then a healthy premium takeover towards $150 is not unreasonable."
Given that Neuren, post FDA approval, is now trading at a price around the same as after successful phase 2 results, why would a buyer pay a 300% premium?
Ann: 2023 Annual Report to shareholders, page-143
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.84 |
Change
0.620(3.07%) |
Mkt cap ! $2.671B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $21.10 | $20.39 | $3.970M | 191.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 345 | $20.82 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.86 | 64 | 3 |
View Market Depth
| Last trade - 12.44pm 26/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |